MabVax Therapeutics Launches Online Corporate Communication Channels and New Website

Oct 23, 2014, 08:00 ET from MabVax Therapeutics Holdings, Inc.

SAN DIEGO, Oct. 23, 2014 /PRNewswire/ -- MabVax Therapeutics Holdings, Inc. (OTCQB: MBVX), a clinical stage oncology drug development company, announced today a suite of online corporate communication channels to maintain on-going direct communication with shareholders and other interested parties. The Company has launched official portals on social media channels including Facebook, Twitter, LinkedIn, Google+, and The Chairman's Blog.

The Chairman's Blog is an online communication portal where MabVax executives will be able to address important topics as they relate to the Company's industry and technology as well as specific points of discussion as they relate to key events at MabVax.  President & CEO J. David Hansen penned the Company's inaugural blog post "Introducing MabVax Therapeutics: Newly Public Company Achieves Multiple Milestones in Recent Quarter." The blog post can be found online at the official MabVax Chairman's Blog profile provided below.

"We have made significant progress on advancing our programs over the last few months and certainly plan to continue over the next year as we take important steps forward in putting three more products into the clinic," commented Hansen.

In addition, the Company has unveiled its new website which provides investors with detailed information and an updated web design.

The website officially launched on Sept. 11, 2014 and can be found at

Links to the new communication tools are here:

About MabVax Therapeutic Holdings, Inc.

MabVax Therapeutics, Inc., (OTCQB: MBVX) became a public company on July 8th of this year through a merger with a listed company and changed its name to MabVax Therapeutics Holdings, Inc.  MabVax is a clinical stage biotechnology company focused on the development of vaccine and antibody based therapies to address unmet medical needs in the treatment of cancer.  MabVax has discovered a pipeline of human monoclonal antibody products based on the protective immune responses generated by patients who have been immunized against targeted cancers. Therapeutic vaccines under development were discovered at MSKCC and are exclusively licensed to MabVax prior to the merger. Additional information about the Company, please visit and connect with the Company on Twitter, LinkedIn, Facebook, and Google+.

Forward Looking Statements

This press release contains "forward-looking statements" regarding matters that are not historical facts, including statements relating to the effects of the merger transaction between Telik and MabVax, anticipated actions taken by the NASDAQ Panel, the potential for the Company's shares to trade on the NASDAQ Capital Market, the Company's expectations regarding the timing and availability of results from its clinical trials, the timing of commencement of manufacturing of the Company's clinical trial supplies and additional clinical trials, and the safety and effectiveness of the Company's drug, vaccine, and antibody-based therapies.  Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements.  Words such as "anticipates," "plans," "expects," "intends," "will," "potential," "hope" and similar expressions are intended to identify forward-looking statements.  These forward-looking statements are based upon current expectations of the Company and involve assumptions that may never materialize or may prove to be incorrect.  Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties.  Detailed information regarding factors that may cause actual results to differ materially from the results expressed or implied by statements in this press release relating to the Company may be found in Telik's periodic filings with the Securities and Exchange Commission, including the factors described in the section entitled "Risk Factors" in its annual report on Form 10-K for the fiscal year ended December 31, 2013 and in the Proxy Statement dated June 3, 2014, as supplemented on June 30, 2014, July 1, 2014 and July 3, 2014.  The parties do not undertake any obligation to update forward-looking statements contained in this press release.

SOURCE MabVax Therapeutics Holdings, Inc.